UCB (OTCMKTS:UCBJF) Shares Gap Down – Should You Sell?

UCB SA (OTCMKTS:UCBJF) gapped down prior to trading on Friday . The stock had previously closed at $266.59, but opened at $250.83. UCB shares last traded at $250.83, with a volume of 8 shares trading hands.

Analyst Upgrades and Downgrades

UCBJF has been the subject of a number of analyst reports. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler reiterated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The stock’s 50 day moving average price is $279.09 and its two-hundred day moving average price is $293.58.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.